Condition (MeSH)
Tooth Diseases
ClinicalTrials.gov lists 3,960 trials for Tooth Diseases or a narrower condition beneath it. GlaxoSmithKline has the most among industry and government lead sponsors, with 56.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
1 more section with rows
79 of the 3,960 trials are tagged with Tooth Diseases itself; the rest are tagged with a narrower condition beneath it.
When did Tooth Diseases trials start? (33)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 10 trials are registered to start in 2027 or later, and not listed here.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
- Other (Unknown)
Top of scale: 392
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 282 |
| 2025 | 385 |
| 2024 | 392 |
| 2023 | 308 |
| 2022 | 269 |
| 2021 | 276 |
| 2020 | 198 |
| 2019 | 274 |
| 2018 | 227 |
| 2017 | 228 |
Showing 10 of 33 earlier years.
Forecast of the full-year count, planned starts included, not rows of this table: about 350 trials starting in 2026 and about 360 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.
Prediction, not a registry value: median of 32 months from start to primary completion across 229 trials still running at the 2026-10-09 snapshot; registered median of 12 months across 2,468 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Tooth Diseases trials in? (9)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 114 |
| Phase 1/2 | 41 |
| Phase 2 | 130 |
| Phase 2/3 | 54 |
| Phase 3 | 153 |
| Phase 4 | 184 |
| Not applicable | 2,652 |
| Observational | 631 |
| Unknown | 1 |
How many Tooth Diseases trials are recruiting? (9)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 280 |
| Recruiting | 272 |
| Enrolling by invitation | 59 |
| Active, not recruiting | 156 |
| Completed | 2,315 |
Showing 5 of 9 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Tooth Diseases trials? (4)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| GlaxoSmithKline | 56 |
| Colgate Palmolive | 51 |
| HALEON | 32 |
| Dentsply Sirona Implants and Consumables | 25 |
Which drugs are being tested for Tooth Diseases? (2)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Stannous Fluoride | 22 |
| Potassium Nitrate Toothpaste | 22 |
Interventions as named in the registry (13)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Fluoride Varnish | 40 |
| Silver diamine Fluoride 38% | 36 |
| Fluoride | 34 |
| Fluoride Toothpaste | 18 |
| Low Level Laser Therapy | 16 |
Showing 5 of 13 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Tooth Diseases trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Cardiac ischemia | 729 | 1 |
| Significant stenosis (PCI, CABG, conservative) | 537 | 1 |
| Tooth Sensitivity (Score of >3) | 77 | 1 |
| Death | 46 | 9 |
| Gingival Erythema | 7 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Tooth Diseases? (109)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Validating clinical characteristic of primary failure of eruption (PFE) associated with PTH1R variants. | Progress in orthodontics | 2021 | Yes |
| Quantitative evaluation of masking effect of resin infiltration on developmental defects of enamel. | Quintessence international (Berlin, Germany : 1985) | 2020 | Yes |
| Evaluation of Blood Clot, Platelet-rich Plasma, Platelet-rich Fibrin, and Platelet Pellet as Scaffolds in Regenerative Endodontic Treatment: A Prospective Randomized Trial. | Journal of endodontics | 2019 | Yes |
| Systemic sclerosis and its oral health implications. | Advances in clinical and experimental medicine : official organ Wroclaw Medical University | 2019 | Yes |
| Clinical and OCT outcomes of a universal adhesive in a randomized clinical trial after 12 months. | Journal of dentistry | 2019 | Yes |
Showing 5 of 109 publications.
Sub-conditions in MeSH (20)
MeSH descendants one level down with at least one trial, most trials first.
+10 more sub-conditions
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.